DIZAL JIANGSU PHARMACEUTICAL CO LTD has a total of 71 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in China, United States and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SHANTON PHARMA CO LTD, GENOSCIENCE PHARMA and CARNA BIOSCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 16 | |
#2 | United States | 11 | |
#3 | Canada | 7 | |
#4 | WIPO (World Intellectual Property Organization) | 7 | |
#5 | Australia | 6 | |
#6 | Brazil | 5 | |
#7 | EPO (European Patent Office) | 5 | |
#8 | Republic of Korea | 5 | |
#9 | Argentina | 3 | |
#10 | Taiwan | 3 | |
#11 | Hong Kong | 1 | |
#12 | Mexico | 1 | |
#13 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Medical technology | |
#5 | Environmental technology | |
#6 | Agriculture |
# | Name | Total Patents |
---|---|---|
#1 | Zhang Xiaolin | 48 |
#2 | Yang Zhenfan | 40 |
#3 | Tsui Honchung | 33 |
#4 | Zeng Qingbei | 30 |
#5 | Li Zhengtao | 20 |
#6 | Qi Changhe | 17 |
#7 | Kettle Jason Grant | 16 |
#8 | Zhu Wei | 12 |
#9 | Chen Xiang | 12 |
#10 | Zou Hao | 12 |
Publication | Filing date | Title |
---|---|---|
WO2020238900A1 | Dna-dependent protein kinase inhibitor | |
CN111480592A | Laboratory mouse marking device and method | |
WO2020211839A1 | Jak1 selective kinase inhibitor | |
TW202024089A | Triazolo-pyrimidine compounds and uses thereof | |
CN111747954A | Pyrazine compounds and uses thereof | |
WO2020035052A1 | Pyrazine compounds and uses thereof | |
AR115457A1 | SELECTIVE NEGATIVE REGULATORS OF THE ESTROGEN RECEPTOR AND THEIR USES | |
WO2019228443A1 | Selective estrogen receptor downregulators and uses thereof | |
AU2019267959A1 | ErbB receptor inhibitors | |
TW201940472A | ERBB/BTK inhibitors | |
EP3353168A1 | Compounds and methods for inhibiting jak |